FI902735A0 - Monoklonal antikropp reaktiv foer en visst vidstraeckt i olika maenskoleukemi- och lymfomaceller foerekommande antigen och metoder foer dess anvaendning i diagnos och vaord. - Google Patents

Monoklonal antikropp reaktiv foer en visst vidstraeckt i olika maenskoleukemi- och lymfomaceller foerekommande antigen och metoder foer dess anvaendning i diagnos och vaord.

Info

Publication number
FI902735A0
FI902735A0 FI902735A FI902735A FI902735A0 FI 902735 A0 FI902735 A0 FI 902735A0 FI 902735 A FI902735 A FI 902735A FI 902735 A FI902735 A FI 902735A FI 902735 A0 FI902735 A0 FI 902735A0
Authority
FI
Finland
Prior art keywords
och
foer
visst
vidstraeckt
vaord
Prior art date
Application number
FI902735A
Other languages
English (en)
Inventor
Ben K Seon
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of FI902735A0 publication Critical patent/FI902735A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FI902735A 1989-06-01 1990-06-01 Monoklonal antikropp reaktiv foer en visst vidstraeckt i olika maenskoleukemi- och lymfomaceller foerekommande antigen och metoder foer dess anvaendning i diagnos och vaord. FI902735A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35950589A 1989-06-01 1989-06-01

Publications (1)

Publication Number Publication Date
FI902735A0 true FI902735A0 (fi) 1990-06-01

Family

ID=23414098

Family Applications (1)

Application Number Title Priority Date Filing Date
FI902735A FI902735A0 (fi) 1989-06-01 1990-06-01 Monoklonal antikropp reaktiv foer en visst vidstraeckt i olika maenskoleukemi- och lymfomaceller foerekommande antigen och metoder foer dess anvaendning i diagnos och vaord.

Country Status (11)

Country Link
US (1) US5407805A (fi)
EP (1) EP0400464A1 (fi)
JP (1) JPH03198795A (fi)
KR (1) KR910000185A (fi)
AU (1) AU5575990A (fi)
CA (1) CA2017528A1 (fi)
FI (1) FI902735A0 (fi)
HU (1) HUT54390A (fi)
IL (1) IL94389A0 (fi)
PT (1) PT94238A (fi)
ZA (1) ZA904229B (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644033A (en) * 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US5648222A (en) * 1994-07-27 1997-07-15 The Trustees Of Columbia University In The City Of New York Method for preserving cells, and uses of said method
CA2256413C (en) 1996-05-31 2007-07-03 Health Research Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US7514232B2 (en) * 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
US6340569B1 (en) 1997-11-12 2002-01-22 University Of Pittsburgh Monoclonal antibody and antigens specific therefor and methods of using same
KR20030071252A (ko) * 2002-02-28 2003-09-03 위프코 주식회사 입체 스캐닝 기법에 의한 대형 조형물 제작방법
WO2006038212A2 (en) * 2004-10-04 2006-04-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for the diagnosis and treatment of cancer
BRPI1107312B1 (pt) * 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
KR102408955B1 (ko) 2019-11-25 2022-06-15 재단법인대구경북과학기술원 3차원 전극 구조체 모델링 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5096810A (en) * 1983-10-31 1992-03-17 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for diagnosis of hairy cell leukemia
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US4724212A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-2 and diagnostic antibody produced thereby
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
US4831117A (en) * 1986-01-03 1989-05-16 Uckun Fatih M Monoclonal antibody specific for human B-cells
US4939083A (en) * 1986-10-30 1990-07-03 La Jolla Cancer Research Foundation Carbohydrate specific to chronic myelogenous leukemia granulocytes

Also Published As

Publication number Publication date
ZA904229B (en) 1991-03-27
IL94389A0 (en) 1991-03-10
EP0400464A1 (en) 1990-12-05
JPH03198795A (ja) 1991-08-29
PT94238A (pt) 1991-02-08
CA2017528A1 (en) 1990-12-01
HUT54390A (en) 1991-02-28
HU903282D0 (en) 1990-10-28
KR910000185A (ko) 1991-01-29
AU5575990A (en) 1990-12-06
US5407805A (en) 1995-04-18

Similar Documents

Publication Publication Date Title
DE69018801D1 (de) Chimärischer anti-cae-antikörper.
FI914908A0 (fi) Ny monoklonal antikropp med ny antigen relaterad till humana tumoerer.
DE68914244D1 (de) Monoklonaler Antikörper.
DE3879452D1 (de) Chimaere antikoerper.
FI903719A0 (fi) Membransepareringssystem och foerfarande foer dess anvaendning.
FI904755A0 (fi) Kombinerad kirurgisk naolsutura-anordning och foerfarande foer dess tillverkning.
DE69111930T2 (de) Künstlicher Antikörper.
FI903228A0 (fi) Enzym-immunitetsprov foer antigen och foer detta aondamaol anvaend fast fas.
DE3885355T2 (de) Monoklonale Antikörper.
FI902735A0 (fi) Monoklonal antikropp reaktiv foer en visst vidstraeckt i olika maenskoleukemi- och lymfomaceller foerekommande antigen och metoder foer dess anvaendning i diagnos och vaord.
FI904495A0 (fi) Oligonukleotidenzymkonjugat och foerfarande dess framstaellning.
FI890815A (fi) Bloeja och foerfarande foer dess tillverkning.
DE3780256D1 (de) Anti-pci-monoklonaler antikoerper.
FI904379A0 (fi) Appliceringshjaelp och dess anvaendning.
NO873488D0 (no) Monoklonale antistoffer.
NO890116L (no) Monoklonale antistoffer.
DE69023717T2 (de) Monoklonaler Antikörper.
IT8821702A0 (it) Nuovo anticorpo monoclonale.
FI832899A (fi) Karcinoembryonal antigen, foerfarande foer dess isolering och dess anvaendning
FI901314A0 (fi) Borstvals och dess borstelement.
FI900401A0 (fi) Foerening och dess anvaendning.
DE68916088T2 (de) Anti-CPBII-monoklonaler Antikörper.
FI881631A (fi) Monoklonal anti-r-bindaemnesantikropp, dess framstaellning och anvaendning.
ATE87031T1 (de) Chimaere antikoerper.
FI894883A0 (fi) Balkartat byggelement och foerfarande foer dess framstaellning.

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: HEALTH RESEARCH, INC.